APEX-STROKE Adaptive Platform Trial for Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 20000 participants.

Also called NCT07784569

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 20,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07784569
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07784569. Randomized; single masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2029-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
APEX-STROKE Adaptive Platform Trial for Stroke
Condition
Stroke
Intervention (Drug)
Early Angong Niuhuang Pill Treatment
Intervention (Drug)
Yiqi Huayu Jiedu Mixture
Intervention (Procedure)
Surgical bundle
Lead sponsor
Fudan University (class: other)
Collaborator
Huashan Hospital (class: other)
Collaborator
Chinese PLA General Hospital (class: other)
Collaborator
Beijing University of Chinese Medicine (class: other)
Collaborator
Hubei College of Traditional Chinese Medicine (class: other)
Collaborator
Guangdong Provincial Hospital of Traditional Chinese Medicine (class: other)

Record details

Record id
cardio:ct-nct07784569
Content hash
4aaf53f6bb70e29c85c05672c4dd1dd2593a61e491708f0dcc31ed463752d20c